CRUINT
VC Fund
Göd, Hungary
CRUINT is a VC fund in Göd focused on Health Care and Neuroscience. CRU network has been providing clinical research services to the pharmaceutical industry for over a decade and basic/academic research services since 2015. In the recent years next to the research activities many new healthcare services were initiated within the EU and in South-East Asia. CRU sites are located in Hungary, Ukraine, Germany,Vietnam and LAO PDR.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries CRUINT invests in
Stages CRUINT invests in
Countries CRUINT invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Peter Kovacs
|
|||
Investment Focus
Industry
- Health Care 1 (100%)
- Neuroscience 1 (100%)
- Therapeutics 1 (100%)
- Pharmaceutical 1 (100%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Peter Kovacs
CEO and Managing Director&Owner
|
CEO and Managing Director&Owner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Neuro Therapia
|
NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. | $12.3M / Series B / Aug 06, 2024 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does CRUINT invest in?
CRUINT invests primarily in Health Care, Neuroscience and Therapeutics startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CRUINT?
Public channels for CRUINT include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CRUINT?
The team at CRUINT includes Peter Kovacs (CEO and Managing Director&Owner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
